Sixty-five billion dollars in two years from the sales of the Covid vaccine. This is what Pfizer estimates to obtain, which analysts have announced to expect sales of 36 billion dollars by the end of the year and another 29 billion next year. The numbers, however, could increase further because the pharmaceutical company has the capacity to produce 4 billion doses a year, but – for the moment – it expects to sell “only” 1.7 billion. The figures announced for next year already exceed analysts’ estimates, but the pharmaceutical group is looking to sign new agreements with other countries to further increase sales in 2022.
Furthermore, it is likely that the green light for the administration of vaccines also in children between the ages of 5 and 11 is likely to arrive soon: the United States has already expressed itself positively on the issue and Europe could soon align.
The weight of the vaccine developed together with BionTech reaches up to 44% of the group’s total annual sales. Sales of the serum, called Comirnaty, have far outstripped those of rivals Moderna Inc and Johnson & Johnson, who are facing production bottlenecks and safety concerns.
“The long-term revenues they might be able to generate from Comirnaty remain unknown and will be determined in part by how the pandemic will evolve, as well as the competitive dynamics within that market,” said Mizuho analyst Vamil. Divan. The vaccine generated $ 13 billion in revenues in the third quarter.